Journal
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Volume 20, Issue 9, Pages 2032-2037Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/01.ATV.20.9.2032
Keywords
arginine; nitric oxide; atherosclerosis; vasodilation
Categories
Funding
- NHLBI NIH HHS [R01 HL58638] Funding Source: Medline
Ask authors/readers for more resources
Asymmetric dimethylarginine (ADMA) is an endogenous and competitive inhibitor of nitric oxide synthase. Plasma levels of this inhibitor are elevated in patients with atherosclerosis and in those with risk factors for atherosclerosis. In these patients, plasma ADMA levels are correlated with the severity of endothelial dysfunction and atherosclerosis, By inhibiting the production of nitric oxide, ADMA may impair blood flow, accelerate atherogenesis, and interfere with angiogenesis. ADMA may be a novel risk factor for vascular disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available